MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma

Abstract

Median survival time was 24 months (range, 2-60 months) among the nine patients who died, whereas median follow-up time in the remaining 19 patients is 33.4 months (range, 4.7-73 months). A trend toward a reduction in MUC4 antigen expression in high-grade tumors (55% expression) compared with low-grade (91% expression) and intermediate-grade (100% expression) tumors is identified (chi square, p =.0975). Patients with tumors expressing MUC4 antigens are at reduced risk of death (hazard ratio [HR], 0.20; p =.0531). Adjustment for pathologic grade, T stage, and age results in a much higher risk of death for patients whose tumors do not express MUC4 antigens, although this does not meet statistical significance (HR, 26.6; p =.1). Analysis of recurrence adjusting for T stage reveals that patients whose tumors do not express MUC4 antigens are at increased risk of recurrence compared with patients whose tumor expresses MUC4 antigens (HR, 6.37; p =.03). ErbB2 receptor staining is noted in seven of 28 patients, with five of these seven showing 2+ and 3+ membrane-staining patterns. Adjustment for pathologic grade and age suggests that patients whose tumors express high levels of ErbB2 (2+, 3+) are at increased risk of death compared with patients with low or no expression of ErbB2 (HR, 2.29; p =.32). MUC4 antigen positivity is seen in two of the five cases with 2+ and 3+ staining for ErbB2. CONCLUSIONS.: These findings suggest MUC4 antigen positivity is associated with reduced risk of death and reduced risk of recurrence and may identify a subset of patients with more favorable prognosis. Although limited by small sample size, analysis reveals ErbB2 overexpression is not consistently associated with MUC4 antigen positivity and might be associated with increased risk of death.

Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: Possible implications for targeted therapy

“…Kernohan et al (28) reported positive immunostaining for HER2 in only 1 out of 6 cases with mucoepidermoid carcinomas. However, Weed et al (23), Cho et al (24) and Press et al (25) reported HER2 overexpression in 25, 36 and 38% of the studied cases. There may be many reasons for the observed differences, including patient selection, methodology of the immunohistochemical procedures, scoring and the definition of HER2 expression.…”

“…HER2 overexpression occurs in 0 to 38% of mucoepidermoid carcinoma (22)(23)(24)(25)(26)(27)(28). So far, no previous study has evaluated the EGFR and HER2 expression in metastases and compared such an expression with that of corresponding primary mucoepidermoid carcinoma.…”

Prognostic significance of membrane-associated mucins 1 and 4 in gastric adenocarcinoma

“…It has been shown that MUC4 expression is related to aggressive tumor behavior or a poor outcome in intrahepatic cholangiocarcinoma, invasive ductal carcinoma of the pancreas, extrahepatic bile duct carcinoma, and lung adenocarcinoma (13)(14)(15)(16)(17). On the other hand, loss of MUC4 expression is related to poor survival in mucoepidermoid carcinoma of the salivary gland, squamous cell carcinoma of the upper aerodigestive system, and adenocarcinoma of lung (18)(19)(20)(21). The function of MUC4 in gastric cancer is not understood.…”

Intraoral Mucoepidermoid Carcinoma of Salivary Glands: Lack of Association Among Clinicopathological Features and Immunoexpression of c-erbB-2 in 29 Cases

“…The amplification and/or overexpressiom of c-erbB-2 in human tumor tissue has been associated with a poor prognosis in ovarian, endometrial and breast carcinoma (Weed et al, 2004). Previous studies of c-erbB-2 expression in salivary gland carcinomas are sparse, comprise heterogeneous subtypes, and show contradictory results (Locati et al, 2005).…”